Proof of Concept
Our model is not theoretical. It is validated by real-world deployment data, built on an existing operational foundation, and supported by a named clinical advisory board.
🇮🇳 India: This already works at scale.
India is the operational proof of concept for the exact model Mandiera is building in Africa — government-partnered, nurse-operated, mobile-first, mass community deployment, validated at scale.
— Government Medical College, Nagpur, Maharashtra
Source: UE LifeSciences public coverage and peer-reviewed clinical studies. Full bibliography available in Series A pitch deck.
🇿🇦 Vision World SA: The fire is already burning.
We are not asking investors to fund a concept. We are asking them to fuel a model that is already working through our operational base at Vision World SA.
✅ HPCSA-Registered Practitioners
All practitioners registered with the Health Professions Council of South Africa — recognised and reimbursed by medical aid schemes. Zero gap to cancer screening reimbursement.
✅ Medical Aid Billing — Live
Zero cost to employer or employee. Medical aids already pay us. This is the exact billing model Mandiera HealthTech scales across 10 schemes and 5 countries.
✅ Named Corporate Clients
Multiple large South African corporates already served. Available for investor due diligence and verification.
✅ Health Trend Reports Delivered
Anonymised workforce health trend reports already produced and delivered to corporate clients — the MedIntelligence™ / MCRI™ concept in practice today.
✅ Practitioner Network Operational
GPs, specialists, registered nurses, dieticians — contracted and operating. The clinical team exists. It is not on a hiring wishlist.
✅ Multi-Province Presence
Geographic diversity already demonstrated. Operational reach extends across multiple South African provinces today.
📊 The Basepaws Precedent: The database is worth more than the business.
Basepaws pitches cat DNA testing on Shark Tank. Valuation: ~$2.5M. Kevin O'Leary invests $125K.
Zoetis — an $80B animal health company — acquires Basepaws for ~$93M. O'Leary's $125K becomes ~$4.5M.
Revenue multiple paid. The asset Zoetis purchased was not the device. It was the genomic database.
Basepaws built a cat DNA database. Zoetis paid $93M for it.
Mandiera is building a human cancer intelligence database across 1.4 billion Africans.
The acquirer of Mandiera will not be buying a screening company. They will be buying Africa's cancer intelligence infrastructure. The scarcity premium on that asset has no ceiling.
Clinical Device Credentials
FDA-Cleared
iBreastExam Class II. 510(k) clearance. USA standard.
SAHPRA Filing
Registration in progress . . .
CE Marked
European conformity. Medical device standard.
ISO 13485
Medical device quality management. Manufacturing certified.